Lorenza Mittempergher, Joseph McKelley, Rajith Bhaskaran, Sahra Uygun, René Bernards, Laura J van ’t Veer, Annuska M Glas, Cynthia X Ma, William Audeh
Cyclin E overexpression is associated with High Risk 70-gene signature, and may indicate intrinsic resistance to CDK4/6 inhibitors
The use of CDK4/6 inhibitors (CDK4/6i) is a promising therapeutic strategy for recurrent ER+, HER2- breast cancers that have escaped previous treatment targeting the endocrine pathway. Considering the potential role of the Cyclin E genes as biomarker of resistance for CDK4/6i, we assessed the expression of CCNE2 in a large series of ESBCs with respect to their MP risk profile.
Read more: SABCS 2019: Cyclin E Expression